GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Exact Sciences Corp (STU:EXK) » Definitions » Cyclically Adjusted Price-to-FCF

Exact Sciences (STU:EXK) Cyclically Adjusted Price-to-FCF : (As of Jun. 09, 2024)


View and export this data going back to 2014. Start your Free Trial

What is Exact Sciences Cyclically Adjusted Price-to-FCF?

Shiller PE for Stocks: The True Measure of Stock Valuation


Exact Sciences Cyclically Adjusted Price-to-FCF Historical Data

The historical data trend for Exact Sciences's Cyclically Adjusted Price-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Exact Sciences Cyclically Adjusted Price-to-FCF Chart

Exact Sciences Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted Price-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Exact Sciences Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted Price-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Exact Sciences's Cyclically Adjusted Price-to-FCF

For the Diagnostics & Research subindustry, Exact Sciences's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Exact Sciences's Cyclically Adjusted Price-to-FCF Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Exact Sciences's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Exact Sciences's Cyclically Adjusted Price-to-FCF falls into.



Exact Sciences Cyclically Adjusted Price-to-FCF Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted Price-to-FCF takes the Free Cash Flow per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/FCF calculation. Because it considers this 10-year average, it's often referred to as the CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF.

Exact Sciences's Cyclically Adjusted FCF per Share for the quarter that ended in Mar. 2024 is calculated as:

For example, Exact Sciences's adjusted Free Cash Flow per Share data for the three months ended in Mar. 2024 was:

Adj_FreeCashFlowPerShare=Free Cash Flow per Share/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=-0.605/131.7762*131.7762
=-0.605

Current CPI (Mar. 2024) = 131.7762.

Exact Sciences Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201406 -0.170 100.560 -0.223
201409 -0.219 100.428 -0.287
201412 -0.324 99.070 -0.431
201503 -0.393 99.621 -0.520
201506 -0.388 100.684 -0.508
201509 -0.390 100.392 -0.512
201512 -0.364 99.792 -0.481
201603 -0.413 100.470 -0.542
201606 -0.360 101.688 -0.467
201609 -0.261 101.861 -0.338
201612 -0.259 101.863 -0.335
201703 -0.308 102.862 -0.395
201706 -0.365 103.349 -0.465
201709 -0.150 104.136 -0.190
201712 -0.261 104.011 -0.331
201803 -0.361 105.290 -0.452
201806 -0.383 106.317 -0.475
201809 -0.403 106.507 -0.499
201812 -0.378 105.998 -0.470
201903 -0.595 107.251 -0.731
201906 -0.355 108.070 -0.433
201909 -0.565 108.329 -0.687
201912 -0.431 108.420 -0.524
202003 -0.384 108.902 -0.465
202006 -0.166 108.767 -0.201
202009 0.382 109.815 0.458
202012 0.497 109.897 0.596
202103 -0.447 111.754 -0.527
202106 0.076 114.631 0.087
202109 -0.394 115.734 -0.449
202112 -0.431 117.630 -0.483
202203 -1.080 121.301 -1.173
202206 -0.666 125.017 -0.702
202209 -0.488 125.227 -0.514
202212 -0.111 125.222 -0.117
202303 -0.353 127.348 -0.365
202306 0.337 128.729 0.345
202309 -0.004 129.860 -0.004
202312 0.175 129.419 0.178
202403 -0.605 131.776 -0.605

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Exact Sciences  (STU:EXK) Cyclically Adjusted Price-to-FCF Explanation

Compared with the regular Price-to-Free-Cash-Flow, which works poorly for cyclical businesses, the Cyclically Adjusted Price-to-FCF smoothed out the fluctuations of free cash flow during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted Price-to-FCF should give similar results to regular Price-to-Free-Cash-Flow.


Exact Sciences Cyclically Adjusted Price-to-FCF Related Terms

Thank you for viewing the detailed overview of Exact Sciences's Cyclically Adjusted Price-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Exact Sciences (STU:EXK) Business Description

Traded in Other Exchanges
Address
5505 Endeavor Lane, Madison, WI, USA, 53719
Exact Sciences Corporation, headquartered in Madison, Wisconsin, provides cancer screening and diagnostic test products in the United States and internationally. Exact's Cologuard screening test, a noninvasive stool-based DNA test, is a pre-cancer screening test for colorectal cancer. The company also competes in the precision oncology market with Oncotype DX, a suite of tissue-based genomic tests for estimating recurrence risk and likelihood of benefit from chemotherapy for breast and colon cancer, and OncoExTra, a liquid-based comprehensive genomic profiling test. It is developing liquid biopsy tests for molecular residual disease, colorectal cancer screening, and multicancer screening, too.